An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Trial Profile

An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Latanoprost (Primary)
  • Indications Angle-closure glaucoma
  • Focus Therapeutic Use
  • Sponsors Eyenovia
  • Most Recent Events

    • 09 Apr 2018 New trial record
    • 02 Apr 2018 According to an Eyenovia media release, full and detailed results are expected in the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top